SINOVAC BIOTECH LTD: retained earnings or deficit
Retained earnings or deficit for SINOVAC BIOTECH LTD. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All SINOVAC BIOTECH LTD financial histories
What this measure means
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
Exact concept: us-gaap:RetainedEarningsAccumulatedDeficit. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 2,815,942,000 | USD | 2026-06-05 | 20-F · 0001193125-26-258534 |
| At date | 2024-12-31 | 6,838,357,000 | USD | 2026-06-05 | 20-F · 0001193125-26-258534 |
| At date | 2023-12-31 | 6,789,335,000 | USD | 2026-04-30 | 20-F · 0001193125-26-194394 |
| At date | 2022-12-31 | 6,804,397,000 | USD | 2026-04-30 | 20-F · 0001193125-26-194394 |
| At date | 2021-12-31 | 6,813,646,000 | USD | 2026-04-30 | 20-F · 0001193125-26-194394 |
| At date | 2020-12-31 | 144,241,000 | USD | 2022-04-29 | 20-F · 0001564590-22-016857 |
| At date | 2019-12-31 | 56,731,000 | USD | 2021-04-22 | 20-F · 0001564590-21-020156 |
| At date | 2018-12-31 | 23,820,000 | USD | 2020-04-30 | 20-F · 0001564590-20-020204 |
| At date | 2017-12-31 | 9,132,000 | USD | 2019-04-29 | 20-F · 0001564590-19-013766 |
| At date | 2016-12-31 | -11,914,000 | USD | 2018-05-11 | 20-F · 0001144204-18-027303 |
| At date | 2015-12-31 | -9,980,000 | USD | 2017-11-22 | 20-F · 0001144204-17-060660 |
| At date | 2014-12-31 | -6,384,000 | USD | 2016-04-25 | 20-F · 0001144204-16-096074 |
| At date | 2011-12-31 | 2,696,227 | USD | 2012-04-12 | 20-F · 0001104659-12-024859 |
| At date | 2010-12-31 | 3,876,084 | USD | 2012-04-12 | 20-F · 0001104659-12-024859 |
Related financial histories
- SINOVAC BIOTECH LTD: total assets
- SINOVAC BIOTECH LTD: total liabilities
- SINOVAC BIOTECH LTD: stockholders equity
- SINOVAC BIOTECH LTD: cash and cash equivalents
- SINOVAC BIOTECH LTD: net income or loss
- SINOVAC BIOTECH LTD: operating cash flow
- SINOVAC BIOTECH LTD: capital expenditure payments
- SINOVAC BIOTECH LTD: contract revenue excluding tax
- SINOVAC BIOTECH LTD: financing cash flow
- SINOVAC BIOTECH LTD: investing cash flow
- SINOVAC BIOTECH LTD: basic weighted-average shares
- SINOVAC BIOTECH LTD: diluted weighted-average shares
- SINOVAC BIOTECH LTD: basic earnings per share
- SINOVAC BIOTECH LTD: diluted earnings per share
- SINOVAC BIOTECH LTD: income tax expense or benefit
- SINOVAC BIOTECH LTD: net property, plant and equipment
- SINOVAC BIOTECH LTD: share-based compensation expense
- SINOVAC BIOTECH LTD: operating income or loss
- SINOVAC BIOTECH LTD: current assets
- SINOVAC BIOTECH LTD: current liabilities
- SINOVAC BIOTECH LTD: goodwill carrying amount
- SINOVAC BIOTECH LTD: net finite-lived intangible assets
- SINOVAC BIOTECH LTD: net current accounts receivable
- SINOVAC BIOTECH LTD: operating expenses
- SINOVAC BIOTECH LTD: net inventory
- SINOVAC BIOTECH LTD: gross profit
- SINOVAC BIOTECH LTD: cost of revenue
- SINOVAC BIOTECH LTD: selling, general and administrative expense
- SINOVAC BIOTECH LTD: research and development expense
Inspect the source
- Entity
- SINOVAC BIOTECH LTD / CIK 0001084201
- Captured
- 2026-09-20T05:21:01.257Z
- SEC response SHA-256
cdda69bdfa617478b5f42edb5b3f08feb3da6c25f952018cb739eb69454da6fa
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001084201.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))